Erudio Healtherudio.com
Drug
Melphalan trials: what clinicians said in public
HCP commentary reports on 2 clinical trials studying melphalan: BMT CTN 0901 and DURGA-6. Each covers what clinicians said in public about one trial, on podcasts, videos and posts, every statement linked to its source. Below them, 7 more trials with public commentary and no report yet.
| Trial | Indication | Phase | Statements | Sources | Size | Checked | Preview |
|---|---|---|---|---|---|---|---|
| BMT CTN 0901 NCT01339910 · Medical College of Wisconsin | acute myeloid leukemia or myelodysplastic syndrome | Phase 3 | 91 | 23 | Focused | Oct 31, 2026 | Preview |
| DURGA-6 NCT07735637 · AstraZeneca | transplant-eligible newly diagnosed multiple myeloma | Phase 3 | 61 | 4 | Focused | Oct 30, 2026 | Preview |
| No report yetTrials with public commentary we haven't built a report for. Size is an estimate of the verified statements the commentary we've indexed so far will yield; final coverage is set when we build the report, within 24 hours of your confirmed order. You never pay more than quoted: a report delivered at a smaller size costs that size's price. Some can also be requested as a free preview. | |||||||
| ALCYONE NCT02195479 · Janssen Research & Development, LLC DeepView → | transplant-ineligible newly diagnosed multiple myeloma | Phase 3 | Deep | View | |||
| EQUULEUS NCT01998971 · Janssen Research & Development, LLC DeepView → | multiple myeloma | Phase 1 | Deep | View | |||
| SWOG S2213 NCT06022939 · SWOG Cancer Research Network DeepView → | newly diagnosed AL amyloidosis | Phase 3 | Deep | View | |||
| GEM2017FIT NCT03742297 · PETHEMA Foundation DeepView → | older fit newly diagnosed multiple myeloma | Phase 3 | Deep | View | |||
| OPTIMIZE NCT06001385 · Center for International Blood and Marrow Transplant Research FocusedView → | hematologic malignancies receiving HLA-mismatched unrelated donor transplantation | Phase 2 | Focused | View | |||
| ACCESS NCT04904588 · Center for International Blood and Marrow Transplant Research FocusedView → | hematologic malignancies | Phase 2 | Focused | View | |||
| OPTIMUM NCT03188172 · University of Leeds FocusedView → | high-risk multiple myeloma and plasma cell leukemia | Phase 2 | Focused | View | |||